Completed PHASE2 INTERVENTIONAL 2-arm NCT01038570

Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo

Evaluation of the Effect of the Oxytocin Administered in Nasal Pulverizing on the Social Skills, the Stress, the Anxiety and the Eating Habits at Grown-up Patients Presenting a Syndrome of Prader-Willi: Pilot Study

Sponsor: University Hospital, Toulouse

Conditions Prader Willi Syndrome

Interventions Physiological serum (Sodium chloride) Syntocinon®/- Spray

Updated 5 times since 2017 Last updated: May 10, 2017 Started: Jun 30, 2009 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Prader Willi Syndrome and is currently completed. University Hospital, Toulouse leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Toulouse

Data source: University Hospital, Toulouse

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hendaye, France